Moss Adams LLP also appointed as new independent registered public accounting firm. May 09, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., May 09, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc….
Read More
Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World’s Most Common Illnesses May 01, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON,…
2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call Today at 5:00…
LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line of highly…
Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea LITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical…
LITTLETON, Colo., Feb. 21, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered…
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements LITTLETON, Colo., January 20, 2023 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing...
Read More
New capital extends cash runway as Vivos seeks to drive revenue growth and manage expenses in 2023 LITTLETON, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or...
Read More
Vivos Therapeutics Announces Pricing of $8 Million Private Placement LITTLETON, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company...
Read More
Approval represents third FDA clearance for Vivos’ oral appliances and first clearance specifically recognizing Vivos’ proprietary core technology LITTLETON Colorado, Jan. 04, 2023 Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ:...
Read More